June 8, 2015
Baltimore, Md. (Embargoed until 10 a.m. EDT, June 8, 2015) — Sally W. Schwarz, MS, RPh, BCNP, professor in radiology at Washington University School of Medicine in St. Louis, Mo., has assumed office as 2015-16 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2015 Annual Meeting, June 6-10, in Baltimore, Md.
“As SNMMI president-elect and a nuclear pharmacist, I want to ensure that safe and effective radiopharmaceuticals for both diagnosis and therapy are made available as soon as possible,” said Schwarz. “In the year ahead, I will be working with both the FDA and CMS on processes to help develop an expedited parallel review process.”
Schwarz’s goals for the coming year include working to raise awareness and understanding of such concerns as isotope availability and radiopharmaceutical development, as well as U.S. Pharmacopeia and regulatory issues. She will also continue development of a database for Investigational New Drug compounds to facilitate access to the chemistry manufacturing and controls information. In addition, Schwarz is interested in developing a qualified person (QP) training program for pharmacists and chemists that would focus on courses needed to release manufactured PET drugs.
In addition to her role as professor at Washington University School of Medicine, Schwarz is co-director of the school’s cyclotron facility and nuclear pharmacy and serves as secretary of the Radioactive Drug Research Committee. Previously, she served as the nuclear pharmacist for the Division of Nuclear Medicine and was the pharmacist representative on the Nuclear Regulatory Advisory Committee.
Within SNMMI, Schwarz currently serves as chair of the Committee on Radiopharmaceuticals and co-chair of the SNMMI Coalition for PET Drug Approval. She has held many positions with the Radiopharmaceutical Sciences Council, including president, and remains involved as the leadership representative. Schwarz is also a member of the FDA Taskforce and previously served on the Clinical Trials Network Manufacturing Committee. In addition, she has dedicated many years to the Missouri Valley SNMMI Chapter, serving as chapter councilor.
Schwarz received her Bachelor of Science degree in pharmacy from the University of Iowa in Iowa City, Iowa, and her Master of Science degree in radiopharmacy from the University of Southern California in Los Angeles, Calif. She is board certified by the American Pharmacist’s Association in nuclear pharmacy.
She serves on the Physical Analysis Expert Committee for the U.S. Pharmacopeia, is chairman of the Washington University Positron-Emitting Radionuclides and Cyclotron Safety Subcommittee, and serves on the editorial board for Nuclear Medicine and Biology and as treasurer for the International Society of Radiopharmaceutical Sciences, among other activities. Schwarz received the Veteran's Administration Traineeship in Radiopharmacy at the University of Southern California as well as the American Pharmacist Association Fellow Award.
She is a member of the American Society of Nuclear Cardiology, Society of Radiopharmaceutical Chemistry and Biology, World Molecular Imaging Society and American Pharmacist Association. Schwarz has published 25 journal articles and 11 book chapters and has been an invited speaker for more than 50 presentations.
Other SNMMI officers elected for 2015-16 are Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, Pasadena, Calif., as president and Bennett S. Greenspan, MD, MS, FACNM, FACR, Augusta, Ga., as vice president-elect. SNMMI Technologist Section officers for 2015-16 are Aaron Scott, MIS, CNMT, NCAA, SNMMI-TS, Fayetteville, Ga., as president and Sara G. Johnson, MBA, CNMT, NCT, FSNMMI-TS, San Diego, Calif., as president-elect.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.